Although the application of next-generation androgen receptor inhibitors such as enzalutamide and abiraterone has successfully improved the survival of patients with advanced prostate cancer, these treatments have also been associated with an elevated incidence of NEPC2,3. This evidence concerns the gene AR and prostate cancer.